1
Clinical Trials associated with MSP1 42-C1/AlhydrogelPhase 1 Study of the Safety and Immunogenicity of MSP1 42-C1/Alhydrogel With and Without CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria
The purpose of this study is to determine the safety of and immune response to a preventive malaria vaccine, MSP1 42-C1/Alhydrogel, in healthy adults. This study will also compare responses to two different doses of the malaria vaccine given with or without the adjuvant CPG 7909.
100 Clinical Results associated with MSP1 42-C1/Alhydrogel
100 Translational Medicine associated with MSP1 42-C1/Alhydrogel
100 Patents (Medical) associated with MSP1 42-C1/Alhydrogel
100 Deals associated with MSP1 42-C1/Alhydrogel